| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 12/27/2013 | WO2013190679A1 Fusion protein, nucleic acid, vector, cell, method for measuring lab, and kit for use in measurement of lab |
| 12/27/2013 | WO2013190555A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/27/2013 | WO2013190047A1 Pharmaceutical formulation |
| 12/27/2013 | WO2013190029A1 Method for the prognosis of a lymphoma and kit for implementing same |
| 12/27/2013 | WO2013189778A1 Bag3 as biochemical serum and tissue marker |
| 12/27/2013 | WO2013189775A1 Bag3 as biochemical serum and tissue marker |
| 12/27/2013 | WO2013152001A3 Anti-hla-b*27 antibodies and uses thereof |
| 12/27/2013 | CA2877814A1 Antigen binding proteins that bind ccr2 |
| 12/27/2013 | CA2877573A1 Antigen binding proteins that bind c-met |
| 12/27/2013 | CA2877363A1 Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| 12/27/2013 | CA2876922A1 Bag3 as biochemical serum and tissue marker |
| 12/27/2013 | CA2876916A1 Kit for diagnosing malignant melanoma |
| 12/27/2013 | CA2876904A1 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| 12/27/2013 | CA2876872A1 Bag3 as biochemical serum and tissue marker |
| 12/27/2013 | CA2876365A1 Novel process for preparation of antibody conjugates and novel antibody conjugates |
| 12/27/2013 | CA2876012A1 Pharmaceutical formulation |
| 12/27/2013 | CA2848291A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/26/2013 | US20130345409 Growth factor |
| 12/26/2013 | US20130345408 Antibody against amyloid precursor protein signal peptide |
| 12/26/2013 | US20130345407 Activation of Sodium Potassium ATPase |
| 12/26/2013 | US20130345406 Stable igg4 antibodies |
| 12/26/2013 | US20130345405 Binding molecules |
| 12/26/2013 | US20130345404 Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation |
| 12/26/2013 | US20130345292 Humanized antibodies against the beta-amyloid peptide |
| 12/26/2013 | US20130345145 Atip3 and biologically active fragments thereof for use in the treatment of cancer |
| 12/26/2013 | US20130345092 T1r taste receptors and genes encoding same |
| 12/26/2013 | US20130344593 Method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human c44-fragment of agrin |
| 12/26/2013 | US20130344566 Inotropic Antibodies And Therapeutic Uses Thereof |
| 12/26/2013 | US20130344538 Human antibodies to the glucagon receptor |
| 12/26/2013 | US20130344537 Mammalian expression vectors and uses thereof |
| 12/26/2013 | US20130344514 Reducing the risk of human anti-human antibodies through v gene manipulation |
| 12/26/2013 | US20130344509 Anti-human trop-2 antibody having an antitumor activity in vivo |
| 12/26/2013 | US20130344104 Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine |
| 12/26/2013 | US20130344094 Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| 12/26/2013 | US20130344091 Compositions and methods for increasing muscle growth |
| 12/26/2013 | US20130344090 Antibodies Against Tissue Factor Pathway Inhibitor (TFPI) |
| 12/26/2013 | US20130344089 Anti oligomer antibodies and uses thereof |
| 12/26/2013 | US20130344087 Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors |
| 12/26/2013 | US20130344086 Stable and soluble antibodies |
| 12/26/2013 | US20130344085 Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| 12/26/2013 | US20130344078 Emp2 antibodies and their therapeutic uses |
| 12/26/2013 | US20130344077 Monoclonal antibodies |
| 12/26/2013 | US20130344076 Antibody conjugates against variant nfkbib and uses thereof |
| 12/26/2013 | US20130344075 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 12/26/2013 | US20130344074 Uses of a dual v region antibody-like protein |
| 12/26/2013 | US20130344073 Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders |
| 12/26/2013 | US20130344072 Anti-VEGF-C Antibodies and Methods Using Same |
| 12/26/2013 | US20130344071 Class I Anti-CEA Antibodies and Uses Thereof |
| 12/26/2013 | US20130344070 Antigen Binding Proteins that Bind CCR2 |
| 12/26/2013 | US20130344069 Antigen Binding Proteins that Bind IGF1R |
| 12/26/2013 | US20130344067 Alk1 receptor and ligand antagonists and uses thereof |
| 12/26/2013 | US20130344064 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
| 12/26/2013 | US20130344058 Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| 12/26/2013 | US20130344057 Binding molecules |
| 12/25/2013 | EP2677319A1 Immunoassay for detection of neurotoxic amino acid associated with neurological disorders |
| 12/25/2013 | EP2676967A2 Methods of treating inflammatory and autoimmune diseases with natalizumab |
| 12/25/2013 | EP2676966A1 BAG3 as biochemical serum and tissue marker |
| 12/25/2013 | EP2676674A1 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| 12/25/2013 | EP2675827A1 Novel modulators and methods of use |
| 12/25/2013 | EP2675826A1 Antibody against the csf-1r |
| 12/25/2013 | EP2675477A2 Treatment of fistulizing crohn's disease |
| 12/25/2013 | EP2443154B1 Bispecific antigen binding proteins |
| 12/25/2013 | EP2358871B1 Erk1/2 phosphorylation site specific antibody |
| 12/25/2013 | EP2297205B1 Use of the irap protein for implementing methods of diagnosis and of prognosis |
| 12/25/2013 | EP1999148B1 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 12/25/2013 | EP1998799B1 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 12/25/2013 | CN103476929A Influenza virus neutralizing antibody and method for screening same |
| 12/25/2013 | CN103476800A Fusion protein |
| 12/25/2013 | CN103476798A Complex in which an anti-cotinine antibody is bound to a binder material of cotinine and a binding substance, and a use therefor |
| 12/25/2013 | CN103476797A Pharmaceutical compositions comprising human antibodies to PCSK9 |
| 12/25/2013 | CN103476796A Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| 12/25/2013 | CN103476795A Antibody Fc variants |
| 12/25/2013 | CN103476794A Antibody against the CSF-1R |
| 12/25/2013 | CN103476793A Subcutaneously administered anti-IL-6 receptor antibody |
| 12/25/2013 | CN103476786A Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method |
| 12/25/2013 | CN103476459A Anticoagulant antidotes |
| 12/25/2013 | CN103476429A Novel modulators and methods of use |
| 12/25/2013 | CN103468735A Preparation methods of recombinant sinopotamon metallothionein (rcMT) and monoclonal antibody thereof |
| 12/25/2013 | CN103468644A Hybridoma cell line capable of generating monoclonal antibody for resisting human D-dimer, preparation method and application |
| 12/25/2013 | CN103467602A Compositions and methods for regulating NK cell activity |
| 12/25/2013 | CN103467601A Method for producing anti-apolipoprotein B (ApoB) multi-antibody serum by using Zhejiang sheep |
| 12/25/2013 | CN103467600A Method for producing anti-apolipoprotein A1 (ApoA1) multi-antibody serum by using Zhejiang sheep |
| 12/25/2013 | CN103467599A Bactrian camel source C-strain E2 VHH and application |
| 12/25/2013 | CN103467598A Completely humanized neutralizing antibody for anti-rabies viruses |
| 12/25/2013 | CN103467582A High throughput screening of tubercle bacillus important antigens, and application of tubercle bacillus important antigens in tuberculosis diagnosis |
| 12/25/2013 | CN103463645A Fish Vibrio. alginolyticus anti-idiotype antibody genetic engineering vaccine and preparation method thereof |
| 12/25/2013 | CN102827279B Anti-neuroepithelial stem cell protein monoclonal antibody with high titer and high specificity and application thereof |
| 12/25/2013 | CN102766640B Method for preparing influenza A virus full-length M2 protein |
| 12/25/2013 | CN102741286B Anti human RANKL monoclonal antibodies developed by PAE technology and uses thereof |
| 12/25/2013 | CN102718865B Humanized anti-EV71 virus neutralizing antibody EV71FabL11, preparation method and application thereof |
| 12/25/2013 | CN102718864B Human anti-EV71 (enterovirus 71) neutralizing antibody EV71FabK7 and preparation method and application thereof |
| 12/25/2013 | CN102702356B Mouse DCF1 specific polyclonal antibody and preparation method of mouse DCF1 specific polyclonal antibody |
| 12/25/2013 | CN102702352B Human anti-EV71 virus neutralization antibody EV71FabL4 and preparation method and application thereof |
| 12/25/2013 | CN102633864B GPC3 antigen polypeptide, anti-GPC3 polyclonal antibody and application thereof |
| 12/25/2013 | CN102276721B Monoclonal antibody for serological diagnosis of liver cancer and application thereof |
| 12/25/2013 | CN102241768B Antibody against hemagglutinin of influenza A H1N1 virus |
| 12/25/2013 | CN102206270B Saxitoxin artificial antigen and anti-saxitoxin antibody, their preparation methods and application |
| 12/25/2013 | CN102127149B Myocardial specificity homeobox part polypeptide and application thereof |
| 12/25/2013 | CN101995460B Ractopamine residual time resolution immunoassay kit and detection method thereof |
| 12/25/2013 | CN101962343B Hapten, artificial antigen and antibody of basic orange as well as preparation method and application thereof |